Teva: fine of 462 million euros from Brussels for anti-competitive activities

The European Commission has just imposed a fine of 462.6 million euros on the Israeli pharmaceutical group Teva for having abused its dominant position in order to delay competition to its flagship drug for the treatment of multiple sclerosis, Copaxone.



Brussels accuses the Israeli laboratory of having artificially extended patent protection for Copaxone and systematically disseminating misleading information on a competing product in order to hinder its entry into the market and its adoption.

  Pascal Lemontel

 WE RECOMMEND YOU

  > Anxiety disorders: a 10-day mental health retreat in Saujon for busy people!

Aging well is becoming a strategy!

In France, there are nearly 42,000 centenarians today, and an estimated 700,000 worldwide. Why do some people reach, or even surpass, the age of 100 without any major health problems? The secret to ...

Nutri-score: better rated products, not necessarily more expensive!

A study by Public Health France, conducted with INRAE, challenges the idea that products with higher Nutri-Score ratings are systematically more expensive. The analysis, covering nearly 28,000 products ...

Medical appointments in France: waiting times are skyrocketing

According to the third barometer of the French Hospital Federation (FHF), getting an appointment with a general practitioner now takes three times longer than in 2019. The average wait time has reached ...

Sleep: Why is it important to get up at regular times?

Who hasn't ever wanted to stay a little longer, or even a lot longer, snuggled up in bed when the alarm clock rings louder than ever? As tempting as it m